 - Company to receive upfront payment of 5 million replacing a later stage regulatory approval milestone of U.S.5 million - Novo Nordisk committing to fund 9 million of the budgeted AEZS-130-P02 Study P02 clinical trial costs for childhood-onset growth hormone deficiency expected to be initiated in Q1 2021 